Icon
+91 94997 68112
Login Register

Zeposia - (0.23, 0.46, and 0.92 mg ; Capsule)

Ozanimod Hydrochloride BRISTOL MYERS SQUIBB
0.23, 0.46, and 0.92 mg ; Capsule
Less Than $1000 mn
None None
Less Than 5
 None
None None
ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • Moderately to severely active ulcerative colitis (UC) in adults.
Yes
Zeposia Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
******* *******
  1. *** **, **** : * **** ** ** ***** *** ***** *** ***** ****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.